AGC Biologics Supports Commercial Production of Provention Bio’s New Type 1 Diabetes (T1D) Therapy, TZIELD™
AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new commercial manufacturing project at its Seattle protein biologics manufacturing site. The CDMO is producing TZIELD™ (teplizumab-mzwv), a new T1D treatment from Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated diseases.
Provention Bio chose AGC Biologics to manufacture TZIELD after the CDMO helped guide the product through PPQ manufacturing and validation batches, and United States Food and Drug Administration (FDA) approval. More than 1.8 million Americans have T1D, an autoimmune disease caused by the destruction of beta cells. TZIELD is the first and only immunomodulatory treatment that delays the onset of Stage 3 T1D in adult and pediatric patients aged 8 years and older. Patients who progress to Stage 3 T1D will eventually require insulin injections for life.
“The multi-year process of shepherding a new therapy from clinical research to commercial launch requires the collaboration of multiple partners, and we are grateful for the ongoing strategic collaboration of AGC Biologics as we begin to deliver TZIELD to patients,” said Provention Bio CEO Ashleigh Palmer. “This is an important milestone for the Type 1 Diabetes community, and we hope the launch of this therapy can truly make an impact on patients and families seeking innovative treatments for the delay of Stage 3 T1D.”
AGC Biologics runs multiple mammalian cGMP manufacturing lines and a variety of scales at its Seattle facility. The campus serves as a center of excellence for formulation and employs the latest fed-batch and perfusion manufacturing processes and houses a new microbial-based manufacturing line system. The AGC Biologics Seattle campus has produced biologics products for 30 years and has a long history of successful inspections by the FDA and commercial production.
“Congratulations to Provention Bio on this game-changing achievement for T1D patients,” said Kevin Ingham, General Manager of AGC Biologics’ Seattle site. “We at AGC Biologics are proud to have helped develop this innovative new medicine and to be manufacturing it for commercial distribution. This achievement demonstrates our Seattle site’s increasing track record in commercial manufacturing, which is aligned with AGC Biologic’s purpose of bringing hope to life.”
To learn more about AGC Biologics’ mammalian and microbial system-based biologics manufacturing site in Seattle, visit www.agcbio.com/facilities/seattle. For more information on the company’s Protein Biologics, Protein DNA (pDNA), Cell Therapy, Viral Vector and Messenger RNA (mRNA) drug product services visit www.agcbio.com.
About Provention Bio, Inc.
Provention Bio, Inc. (Nasdaq: PRVB) is a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated diseases. The Company's pipeline includes clinical-stage product candidates that have demonstrated in pre-clinical or clinical studies proof-of-mechanism and/or proof-of-concept in autoimmune diseases, including T1D, celiac disease and lupus. Visit www.ProventionBio.com for more information and follow us on Twitter: @ProventionBio.
About AGC Biologics
AGC Biologics is a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO) with a strong commitment to delivering the highest standard of service as we work side-by-side with our clients and partners, every step of the way. We provide world-class development and manufacture of mammalian and microbial-based therapeutic proteins, plasmid DNA (pDNA), messenger RNA (mRNA), viral vectors, and genetically engineered cells. Our global network spans the U.S., Europe, and Asia, with cGMP-compliant facilities in Seattle, Washington; Boulder and Longmont, Colorado; Copenhagen, Denmark; Heidelberg, Germany; Milan, Italy; and Chiba, Japan and we currently employ more than 2,000 employees worldwide. Our commitment to continuous innovation fosters the technical creativity to solve our clients’ most complex challenges, including specialization in fast-track projects and rare diseases. AGC Biologics is the partner of choice. To learn more, visit www.agcbio.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda Completes Acquisition of Nimbus Therapeutics’ TYK2 Program Subsidiary9.2.2023 00:30:00 CET | Press release
Takeda (TSE:4502/NYSE:TAK) today announced that it has completed an acquisition of all shares of Nimbus Lakshmi, Inc. (“Lakshmi”) from Nimbus Therapeutics, LLC (“Nimbus”), on February 8, 2023 (EST), as set forth in the share purchase agreement, following clearance from the United States Federal Trade Commission and a satisfaction of other closing conditions. The agreement had been announced on December 13, 2022: “Takeda to Acquire 100% Ownership of Nimbus Therapeutics’ TYK2 Program Subsidiary”. Following the completion of this transaction, Takeda has now acquired TAK-279, formerly known at Nimbus as NDI-034858. With Phase 2b data to be presented in Q4 FY2022 and Phase 3 study in psoriasis expected to start in 2023, TAK-279 has the potential to demonstrate best-in-class efficacy, safety and convenience in psoriasis as well as multiple other immune-mediated diseases, including inflammatory bowel disease, psoriatic arthritis and systemic lupus erythematosus. This acquisition strengthens T
O-RAN ALLIANCE Events and Demos at MWC Barcelona Showcasing O-RAN Ecosystem Progress9.2.2023 00:24:00 CET | Press release
Join us for O-RAN ALLIANCE Ecosystem Briefing, February 28, 2023 at MWC Barcelona This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230208005994/en/ O-RAN ALLIANCE plans to hold its next industry event on Tuesday, February 28, 2023 from 15:30-16:30 CET at the Deutsche Telekom booth (Hall 3, Stand 3M31). The event will include: An update on O-RAN’s progress and future directions by Alex Jinsung Choi, Chair of the Board of O-RAN ALLIANCE and SVP Group Technology at Deutsche TelekomStefan Engel-Flechsig, O-RAN ALLIANCE COO Views on important areas supporting widespread adoption of open RAN, featuring leading operators from Asia, Europe and the Americas: Open RAN testing and integration – by Chih-Lin I, Chief Scientist from China Mobile and Co-chair of O-RAN Technical Steering Committee Open RAN security – by Claire Chauvin, Strategy Architecture and Standardization Director at Orange Open software for the RAN – by Rob Soni, VP RAN
IFF Reports Fourth Quarter and Full Year 2022 Results8.2.2023 22:31:00 CET | Press release
International Flavors & Fragrances Inc. (NYSE: IFF) reported financial results for the fourth quarter and full year ended December 31, 2022. Management Commentary “IFF delivered solid financial results in 2022 in what continues to be a challenging operating environment,” said IFF CEO Frank Clyburn. “Throughout the year our team successfully executed on what we could control – pricing, productivity and portfolio optimization – to generate strong sales growth, enhance profitability and reduce our debt. At the same time, we introduced a refreshed growth-focused strategy, that deepens our commitment to customers, prioritizes our highest-return businesses, and expands productivity to drive long-term profitable growth. We are confident that these are the right strategies to navigate near-term challenges – as we balance growth, profitability and cash flow generation – and deliver long-term value creation for our shareholders.” Fourth Quarter2022 Consolidated Financial Results Reported net sal
Global Partners Announce Innovations for Marine Managers to Help Our Oceans With Private Sector Support From Mary Kay Inc.8.2.2023 18:03:00 CET | Press release
Ocean conservation managers and practitioners, global experts, and high-level officials are convening for the Fifth International Marine Protected Area Congress (IMPAC5) from February 3-9 in Vancouver, Canada, to take a stand to protect the ocean. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230208005180/en/ MPAth, short for Marine Protected Area Tool Hub, is a free online resource for seascape stakeholders at every level. It uses the same problem-solving matrix honed by marine experts to guide users through a learning journey and help them address their most pressing challenges on sustainable livelihoods, financing, effectiveness, and climate change. (Credit: UN Environment Programme) IMPAC5 is known as the preeminent conference for the exchange of knowledge within the global community of marine conservation managers, practitioners, and decision makers. It provides the opportunity to highlight the latest science and share
Morgan Stanley Hosts First Global Demo Day for Startups in Inclusive Ventures Lab8.2.2023 16:23:00 CET | Press release
Morgan Stanley (NYSE: MS) today is hosting its first global in-person Demo Day, with 10 participating companies from the US and Europe, the Middle East and Africa (EMEA). The cohort companies, all founded by women, will pitch over 200 investors, as well as potential business partners and customers. Over the past five months, Morgan Stanley’s Inclusive Ventures Lab has supported its eighth cohort of technology-enabled startups in the post-seed to Series A funding round stage, offering an intensive accelerator program designed to provide a variety of mentorship opportunities and business-growth resources from across the Firm’s network. “We are on a mission to change the investing landscape for underrepresented founders. Through our accelerator program we are providing promising startups with much-needed capital, the broad resources of Morgan Stanley and access to investors,” said Selma Bueno, Managing Director and Global Head of the Inclusive Ventures Group. “Today’s Demo Day showcases i